Teijin & BioVaram Partner to Advance Regenerative Medicine and Medical Devices

• Teijin and BioVaram sign MoU to expand regenerative medicine and implantable device access in India and Japan.
• Collaboration to include commercialization of Teijin’s cardiovascular patch, SYNFOLIUM, in India.
• Partnership to bring BioVaram’s biotech innovations to Japan’s healthcare market.

Hyderabad-based biotechnology company BioVaram has signed a Memorandum of Understanding (MoU) with Japan’s Teijin Limited to co-develop and expand access to next-generation regenerative medicine products and implantable medical devices in India and Japan.

BioVaram, an incubated startup at the University of Hyderabad and the brand of UR Advanced Therapeutics Pvt Ltd, said the partnership will focus on leveraging both companies’ strengths in biotechnology, medical technology, and market access.

Under the agreement, the two firms will explore regulatory pathways and commercialization of SYNFOLIUM, a cardiovascular repair patch developed by Teijin Medical Technologies Co., Ltd, in the Indian market. The collaboration will also pave the way for the introduction of regenerative medicine products from Japan Tissue Engineering Co., Ltd (part of the Teijin Group) into India.

Jaganmohan Reddy, BioVaram’s Founder and CEO, added that the collaboration will enhance the company’s R&D and manufacturing capabilities while enabling global outreach for Indian biotech innovations.

Also Read: Ericsson Expands R&D Presence in India with New 5G Software Unit in Bengaluru

In return, Teijin will help bring BioVaram’s advanced biotech innovations, including exosome-based diagnostics and therapeutics, extracellular matrix mimics, and bio-derived materials such as Type I atelocollagen, to the Japanese market.

Takayuki Nakano, Executive General Manager at Teijin, said the partnership marks an important step in Teijin’s global expansion in regenerative medicine and implantable medical devices.